|Videos|October 11, 2021
GenesisCare physicians discuss PSMA-PET imaging agent Pylarify
Advertisement
GenesisCare doctors Kishore K. Dass, MD, Anurag Agarwal, MD, and Jerry Singer, MD, share their expert insight on the novel PSMA-PET imaging diagnostic Pylarify (piflufolastat F 18), which is FDA approved for use in patients with prostate cancer. The first US patient to receive Pylarify was treated at the GenesisCare facility in Boca Raton, Florida, where these doctors work.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD
2
CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom
3
Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy
4
How ARASEC and ARACOG are reshaping mCSPC treatment choices
5






